Notice of Correction to PAR-21-166 "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)"
Notice Number:
NOT-CA-21-119

Key Dates

Release Date:

September 23, 2021

Related Announcements

PAR-21-166 - Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to correct the expiration date and to add clarification to the Research Strategy section of Funding Opportunity Announcement (FOA) PAR-21-166, "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)".

The following sections of PAR-21-166 have been modified:

Currently Reads:

Part 1. Overview Information

Key Dates

Posted Date

March 25, 2021

Open Date (Earliest Submission Date)

May 05, 2021

Letter of Intent Due Date(s)

Not Applicable

The following table includes NIH standard due dates marked with an asterisk.

Application Due Dates

Review and Award Cycles

New

Renewal / Resubmission / Revision (as allowed)

AIDS

Scientific Merit Review

Advisory Council Review

Earliest Start Date

June 05, 2021 *

July 05, 2021 *

Not Applicable

November 2021

January 2022

April 2022

October 05, 2021 *

November 05, 2021 *

Not Applicable

March 2022

May 2022

July 2022

February 05, 2022 *

March 05, 2022 *

Not Applicable

July 2022

October 2022

December 2022

June 05, 2022 *

July 05, 2022 *

Not Applicable

November 2022

January 2023

April 2023

October 05, 2022 *

November 05, 2022 *

Not Applicable

March 2023

May 2023

July 2023

February 05, 2023 *

March 05, 2023 *

Not Applicable

July 2023

October 2023

December 2023

June 05, 2023 *

July 05, 2023 *

Not Applicable

November 2023

January 2024

April 2024

October 05, 2023 *

November 05, 2023 *

Not Applicable

March 2024

May 2024

July 2024

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

January 08, 2024

Due Dates for E.O. 12372

Not Applicable

Modified to Read (changes shown in bold italics):

Part 1. Overview Information

Key Dates

Posted Date

March 25, 2021

Open Date (Earliest Submission Date)

May 05, 2021

Letter of Intent Due Date(s)

Not Applicable

The following table includes NIH standard due dates marked with an asterisk.

Application Due Dates

Review and Award Cycles

New

Renewal / Resubmission / Revision (as allowed)

AIDS

Scientific Merit Review

Advisory Council Review

Earliest Start Date

June 05, 2021 *

July 05, 2021 *

Not Applicable

November 2021

January 2022

April 2022

October 05, 2021 *

November 05, 2021 *

Not Applicable

March 2022

May 2022

July 2022

February 05, 2022 *

March 05, 2022 *

Not Applicable

July 2022

October 2022

December 2022

June 05, 2022 *

July 05, 2022 *

Not Applicable

November 2022

January 2023

April 2023

October 05, 2022 *

November 05, 2022 *

Not Applicable

March 2023

May 2023

July 2023

February 05, 2023 *

March 05, 2023 *

Not Applicable

July 2023

October 2023

December 2023

June 05, 2023 *

July 05, 2023 *

Not Applicable

November 2023

January 2024

April 2024

October 05, 2023 *

November 05, 2023 *

Not Applicable

March 2024

May 2024

July 2024

February 05, 2024 * March 05, 2024 * Not Applicable July 2024 October 2024 December 2024

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

May 08, 2024

Due Dates for E.O. 12372

Not Applicable

Additionally, modifications have also been made to the following section:

Currently Reads:  

Section IV. Application and Submission Information

2. Content and Form of Application Submission

PHS 398 Research Plan

2. Background and Significance: The application should clearly state a cancer related problem, its importance, and the potential benefits gained via proposed mitigation or solution.

4. Approach: Provide a detailed, rational plan for translation of the new method or technology that addresses a cancer problem. Indicate why it is ready to be translated. Provide preliminary data that support the study plan, feasibility, and approach to validation. For context, include a description of expected user groups and their environments.

Modified to Read (changes shown in bold italics):

Section IV. Application and Submission Information

2. Content and Form of Application Submission

PHS 398 Research Plan

2. Background and Significance: The application should clearly state a biomedical related problem, its importance, and the potential benefits gained via proposed mitigation or solution.

4. Approach: Provide a detailed, rational plan for translation of the new method or technology that addresses a biomedical problem. Indicate why it is ready to be translated. Provide preliminary data that support the study plan, feasibility, and approach to validation. For context, include a description of expected user groups and their environments

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Miguel R. Ossandon, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5714
Email: ossandom@mail.nih.gov

Christopher Hartshorn, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-781-3315
Email: christopher.hartshorn@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices